| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/11/2002 | WO2002029050A2 Regulation of human secretin receptor-like gpcr |
| 04/11/2002 | WO2002029047A2 Regulation of human gpcr-like protein |
| 04/11/2002 | WO2002029045A2 Method for the production of vitamin k-dependent proteins |
| 04/11/2002 | WO2002029044A2 Modulation of the transcription of pro-inflammatory gene products |
| 04/11/2002 | WO2002029040A2 25219, a novel human aminotransferase and uses therefor |
| 04/11/2002 | WO2002029038A2 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 04/11/2002 | WO2002029036A2 Lipid metabolism enzymes |
| 04/11/2002 | WO2002029031A2 Isoprenoid-dependent ras anchorage (idra) proteins |
| 04/11/2002 | WO2002029026A2 Human proteases and polynucleotides encoding the same |
| 04/11/2002 | WO2002029025A2 Factor vii glycoforms |
| 04/11/2002 | WO2002029023A1 Nicastrin protein |
| 04/11/2002 | WO2002028997A2 Methods of isolating bipotent hepatic progenitor cells |
| 04/11/2002 | WO2002028909A1 Starch |
| 04/11/2002 | WO2002028908A1 Pharmaceutically acceptable starch |
| 04/11/2002 | WO2002028906A2 Regulation of human sphingosine kinase-like protein |
| 04/11/2002 | WO2002028902A2 Nectin polypeptides, polynucleotides, methods of making and use thereof |
| 04/11/2002 | WO2002028900A2 Tach: new tnf-receptor family nucleic acids and polypeptides |
| 04/11/2002 | WO2002028899A1 Human prostate specific g-protein receptor hpraj70 |
| 04/11/2002 | WO2002028897A2 Human g-protein coupled receptor and uses thereof |
| 04/11/2002 | WO2002028895A2 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 04/11/2002 | WO2002028894A1 Gene relating to drug tolerance and utilization thereof |
| 04/11/2002 | WO2002028892A1 Von willebrand factor-binding proteins from staphylococci |
| 04/11/2002 | WO2002028891A2 Listeria inocua, genome and applications |
| 04/11/2002 | WO2002028889A2 Haemophilus influenzae antigens and corresponding dna fragments |
| 04/11/2002 | WO2002028887A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours |
| 04/11/2002 | WO2002028886A2 Caloxins their isolation and use |
| 04/11/2002 | WO2002028885A1 N-alkylglycine trimeres capable of protecting neurons against excitotoxic aggressions and compositions containing said trimeres |
| 04/11/2002 | WO2002028883A1 Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| 04/11/2002 | WO2002028882A1 Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism |
| 04/11/2002 | WO2002028881A1 Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| 04/11/2002 | WO2002028878A1 Antisense modulation of smad6 expression |
| 04/11/2002 | WO2002028521A1 Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 04/11/2002 | WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | WO2002028439A2 Transferrin-polycation/dna complexes for the systemic treatment of tumour diseases using cytotoxic proteins |
| 04/11/2002 | WO2002028436A1 Absorption enhancers |
| 04/11/2002 | WO2002028425A2 Methods for treating muscle injuries |
| 04/11/2002 | WO2002028421A1 Methods of inhibition of stenosis and/or sclerosis of the aortic valve |
| 04/11/2002 | WO2002028420A2 Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules |
| 04/11/2002 | WO2002028419A2 Chemokine mutants in the treatment of multiple sclerosis |
| 04/11/2002 | WO2002028418A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 04/11/2002 | WO2002028417A1 Methods for treating joints using viscoelastic collagen solutions |
| 04/11/2002 | WO2002028416A1 Preventives/remedies for hemolytic anemia |
| 04/11/2002 | WO2002028415A1 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/11/2002 | WO2002028414A1 Compositions and methods for wt1 specific immunotherapy |
| 04/11/2002 | WO2002028413A1 Bone health compositions derived from milk |
| 04/11/2002 | WO2002028412A1 Novel use of peptide |
| 04/11/2002 | WO2002028411A1 Compounds for sustained release of orally delivered drugs |
| 04/11/2002 | WO2002028410A1 Perilipin as a target for regulation of body weight, muscle mass and diabetes |
| 04/11/2002 | WO2002028408A2 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 04/11/2002 | WO2002028407A1 Methods of recovering heat shock proteins and complexes thereof |
| 04/11/2002 | WO2002028406A2 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases |
| 04/11/2002 | WO2002028405A2 Method for inducing onset of the reproductive cycle of female breeding animals |
| 04/11/2002 | WO2002028375A1 A controlled-release, parenterally administrable microparticle preparation |
| 04/11/2002 | WO2002028374A1 Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same |
| 04/11/2002 | WO2002028372A2 Systemic delivery of compounds through non-invasive bladder administration |
| 04/11/2002 | WO2002028371A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 04/11/2002 | WO2002028370A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 04/11/2002 | WO2002028355A2 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | WO2002028352A2 A modulator of antiestrogen pharmacology |
| 04/11/2002 | WO2002028349A2 Method of treating cancer using dithiocarbamate derivatives |
| 04/11/2002 | WO2002028332A1 Malleable paste with allograft bone reinforcement for filling bone defects |
| 04/11/2002 | WO2002028165A2 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/11/2002 | WO2002012275A3 Lat peptides and their use in assays for identifying immunosuppressants |
| 04/11/2002 | WO2002009650A3 Methods and compositions for the repair and/or regeneration of damaged myocardium |
| 04/11/2002 | WO2002007514A3 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 04/11/2002 | WO2002006300A3 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis |
| 04/11/2002 | WO2002003911A3 Prevention and treatment of alzheimer's disease |
| 04/11/2002 | WO2002000891A3 Human napsin-like aspartyl protease |
| 04/11/2002 | WO2002000725A3 G-protein coupled receptor org10 |
| 04/11/2002 | WO2001098328A3 Glycopeptide phosphonate derivatives |
| 04/11/2002 | WO2001092581A8 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 04/11/2002 | WO2001092308A3 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 04/11/2002 | WO2001091698A3 Genetically-engineered mhc molecules |
| 04/11/2002 | WO2001090391A3 Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution |
| 04/11/2002 | WO2001090300A3 Snap back stealth oligonucleotide |
| 04/11/2002 | WO2001089298A3 Compositions and methods of nematode control |
| 04/11/2002 | WO2001087342A3 Delivery devices for treatment of vascular disease |
| 04/11/2002 | WO2001087323A3 Method for treating cartilage disorders |
| 04/11/2002 | WO2001085935A3 Endothelial differentiation gene 6-like g protein coupled receptor |
| 04/11/2002 | WO2001085200A3 Recombinant human cln2 protein and methods of its production and use |
| 04/11/2002 | WO2001083556A3 Retina xr receptor |
| 04/11/2002 | WO2001083031A3 Topical composition for the treatment of psoriasis and related skin disorders |
| 04/11/2002 | WO2001081558A3 13295 novel protein kinase molecules and uses therefor |
| 04/11/2002 | WO2001080864A3 Chemical modification of mammalian urine and blood |
| 04/11/2002 | WO2001078765A3 Prophylaxis and treatment of diabetes mellitus 1 using proteolytic enzymes |
| 04/11/2002 | WO2001075107A3 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis |
| 04/11/2002 | WO2001074898A8 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 04/11/2002 | WO2001074856A3 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 04/11/2002 | WO2001072278A3 Method for administering insulin to the buccal region |
| 04/11/2002 | WO2001070989A3 Genetically modified plants and plant cells comprising heterologous heavy metal transport and complexation proteins |
| 04/11/2002 | WO2001070971A3 Regulation of human mas oncogene-related g protein-coupled receptor |
| 04/11/2002 | WO2001070814A3 Regulation of human rta-like g protein-coupled receptor |
| 04/11/2002 | WO2001070174A3 Vegf-modulated genes and methods employing them |
| 04/11/2002 | WO2001068822A3 Method of treating phenylketonuria and means therefor |
| 04/11/2002 | WO2001068069A3 Pharmaceutical composition comprising paracetamol |
| 04/11/2002 | WO2001066758A3 25934, a novel fatty acid desaturase and uses therefor |
| 04/11/2002 | WO2001066574A3 Cryptococcal mannoproteins or equivalents thereof for use in modulating neutrophil migration |
| 04/11/2002 | WO2001066147A3 Antimicrobial compounds and formulations |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/11/2002 | WO2001063293A3 Diagnosis and treatment of schizophrenia |